Skip to main content

Spyre Therapeutics, Inc.

corporate_fare Company Profile

Spyre Therapeutics, Inc.

SYRE·NASDAQ·Life Sciences·CIK 0001636282

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing long-acting antibodies and antibody combinations for inflammatory bowel disease ("IBD") and rheumatic diseases. The company's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23, which are being developed as both monotherapies and pair-wise combinations. Spyre's strategy involves three main pillars: advancing a portfolio of next-generation monotherapies, evaluating IBD combinations, and expanding its anti-TL1A program into additional indications. The next-generation monotherapy antibody candidates, SPY001, SPY002, and SPY003, target α4β7, TL1A, and IL-23, respectively. These candidates are engineered for optimized potency, selectivity, and pharmacokinetics ("PK") against validated IBD targets. They incorporate Fc domain modifications called YTE substitutions to increase pharmacokinetic half-life and are formulated as high-concentration, citrate-free formulations. These attributes aim to enable quarterly or twice annual subcutaneous ("SC") maintenance dosing. The company is also exploring fixed-dose-combinations of its investigational antibodies. The anti-TL1A program is being expanded into additional indications, starting with rheumatoid arthritis ("RA"), psoriatic arthritis ("PsA"), and axial spondyloarthritis ("axSpA").

Spyre Therapeutics, Inc. (NASDAQ:SYRE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 34 items for SYRE at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Spyre Therapeutics Expands SPY003 License to All Therapeutic Areas
  • Spyre Therapeutics Secures $435M in Public Offering and Reports Positive SPY001 Phase 2 Data
  • Spyre Therapeutics Closes Upsized $463.5M Public Offering to Fund Clinical Programs
  • Spyre Therapeutics Closes $463.5M Public Offering, Underwriters Fully Exercise Option
  • Spyre Therapeutics Prices Upsized $403M Public Offering to Fund Clinical Pipeline Advancement

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$155.2M
Op. Cash Flow
-$169.25M
Operating Income
-$209.56M
Cash & Equivalents
$85.72M
Debt / Equity
0.00×
Shares Outstanding
78.19M sh
Source: 10-K · filed 2026-02-19 · accession 0001636282-26-000020
$93.47
52-week range · as of 2026-11-03 $21.14 – $110.17
Market cap
$8.88B
Volume
805.4K (0.8× avg)
3-mo avg 1M
Live data · 2026-11-22 13:02 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SYRE - Filings & News (Page 2)

SYRE
Jun 01, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $70.54
Real-time Price: $93.47 info
Change: +$22.93 (+33%) info
Market Cap: $8.877B info
SYRE
May 05, 2026, 8:00 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $68.13
Real-time Price: $93.47 info
Change: +$25.34 (+37%) info
Market Cap: $8.877B info
SYRE
Apr 16, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $69.76
Real-time Price: $93.47 info
Change: +$23.71 (+34%) info
Market Cap: $8.877B info
SYRE
Apr 16, 2026, 4:15 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $69.76
Real-time Price: $93.47 info
Change: +$23.71 (+34%) info
Market Cap: $8.877B info
SYRE
Apr 15, 2026, 5:42 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $68.15
Real-time Price: $93.47 info
Change: +$25.32 (+37%) info
Market Cap: $8.877B info
SYRE
Apr 14, 2026, 10:38 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $62.25
Real-time Price: $93.47 info
Change: +$31.22 (+50%) info
Market Cap: $8.877B info
SYRE
Apr 13, 2026, 5:26 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $62.35
Real-time Price: $93.47 info
Change: +$31.12 (+50%) info
Market Cap: $8.877B info
SYRE
Apr 13, 2026, 4:46 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $62.15
Real-time Price: $93.47 info
Change: +$31.32 (+50%) info
Market Cap: $8.877B info
SYRE
Apr 13, 2026, 4:29 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $63.61
Real-time Price: $93.47 info
Change: +$29.86 (+47%) info
Market Cap: $8.877B info
SYRE
Apr 13, 2026, 7:46 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $63.17
Real-time Price: $93.47 info
Change: +$30.30 (+48%) info
Market Cap: $8.877B info
SYRE
Apr 13, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $51.85
Real-time Price: $93.47 info
Change: +$41.62 (+80%) info
Market Cap: $8.877B info
SYRE
Feb 19, 2026, 4:33 PM EST
Filing Type: S-3
Importance Score:
8
Price at Filing: $37.81
Real-time Price: $93.47 info
Change: +$55.66 (+147%) info
Market Cap: $8.877B info
SYRE
Feb 19, 2026, 4:01 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $37.81
Real-time Price: $93.47 info
Change: +$55.66 (+147%) info
Market Cap: $8.877B info
SYRE
Jan 12, 2026, 9:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $31.05
Real-time Price: $93.47 info
Change: +$62.42 (+201%) info
Market Cap: $8.877B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets